As such, it is imperative to design innovative and combination therapies by exploring key PDAC tumor vulnerabilities, deploying precision medicine tools, and shutting down the major tumor-driving K-RAS signaling pathway in order to achieve a curative measure in the future [1,2,6,35,65]. The gene discussed is KRAS; the disease is neoplasm.